Rotaviruses: immunological determinants of protection against infection and disease
- PMID: 7817873
- PMCID: PMC7130874
- DOI: 10.1016/s0065-3527(08)60329-2
Rotaviruses: immunological determinants of protection against infection and disease
Abstract
Although studies of rotavirus immunity in experimental animals and humans have often yielded conflicting data, a preponderance of evidence supports the following answers to the questions initially posed. 1. What is the importance of virus serotype in formulating an optimal vaccine? Both vp4 and vp7 induce virus-neutralizing antibodies after either natural infection or immunization; the capacity of vp4 to induce rotavirus-specific neutralizing antibodies is probably greater than that of vp7. However, protection against disease after immunization of infants and young children is induced by strains heterotypic to the challenge virus (e.g., immunization with WC3 induces protection against disease induced by serotypically distinct human G1 strains). In addition, oral inoculation of infants with primate or bovine reassortant rotaviruses containing genes that encode human vp7 has not consistently induced a higher level of protection against challenge than that induced by parent animal rotaviruses (see Table I). Therefore, although vp4 or vp7 or both are probably important in inducing protection against challenge, it has not been clearly demonstrated that inclusion of the epidemiologically important human (as distinct from animal) P or G type is important in protection against human disease. 2. Which immunological effector arm most likely protects against rotavirus disease? No immunological effector arm clearly explains protection against heterotypic challenge. Protection against disease is not predicted by rotavirus-specific neutralizing antibodies in serum. Rotavirus-specific, binding sIgA in feces [detected by enzyme-linked immunosorbent assay (ELISA)] induced after natural infection does correlate with protection against disease induced by subsequent infection. However, protection after immunization with WC3 may occur in the absence of a detectable fecal sIgA response. The relationship between rotavirus-binding sIgA and sIgA-mediated neutralizing activity directed against the challenge virus remains to be determined. Binding rotavirus-specific sIgA in feces detected by ELISA may only be a correlate of other events occurring at the intestinal mucosal surface. The presence of broadly cross-reactive, rotavirus-specific CTLs at the intestinal mucosal surface of mice acutely after infection is intriguing. It would be of interest to determine the degree to which the presence of cross-reactive, rotavirus-specific CTLs in the circulation is predictive of the presence of virus-specific CTLs among intestinal lymphocytes and protection against challenge. Unfortunately, studies of virus-specific CTLs are difficult to perform in children. 3. By what means is virus antigen best presented to the host to elicit a protective immune response? Oral inoculation may not be necessary to induce a protective, virus-specific immune response at the intestinal mucosal surface.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4.Pediatr Infect Dis J. 2004 Mar;23(3):206-11. doi: 10.1097/01.inf.0000115503.55212.bf. Pediatr Infect Dis J. 2004. PMID: 15014293
-
Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles.J Virol. 1999 Jun;73(6):4813-22. doi: 10.1128/JVI.73.6.4813-4822.1999. J Virol. 1999. PMID: 10233942 Free PMC article.
-
WC3 reassortant vaccines in children.Arch Virol Suppl. 1996;12:187-98. doi: 10.1007/978-3-7091-6553-9_20. Arch Virol Suppl. 1996. PMID: 9015115 Review.
-
The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants.J Infect Dis. 1996 Sep;174 Suppl 1:S73-80. doi: 10.1093/infdis/174.supplement_1.s73. J Infect Dis. 1996. PMID: 8752294 Review.
-
Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype.J Virol. 1986 Nov;60(2):491-6. doi: 10.1128/JVI.60.2.491-496.1986. J Virol. 1986. PMID: 3021983 Free PMC article.
Cited by
-
Establishment of Sandwich ELISA for Quality Control in Rotavirus Vaccine Production.Vaccines (Basel). 2022 Feb 5;10(2):243. doi: 10.3390/vaccines10020243. Vaccines (Basel). 2022. PMID: 35214701 Free PMC article.
-
The dark side of the gut: Virome-host interactions in intestinal homeostasis and disease.J Exp Med. 2021 May 3;218(5):e20201044. doi: 10.1084/jem.20201044. J Exp Med. 2021. PMID: 33760921 Free PMC article. Review.
-
Viral gastroenteritis: Causes, pathophysiology, immunology, treatment, and epidemiology.Perspect Med Virol. 2003;9:1-8. doi: 10.1016/S0168-7069(03)09001-3. Epub 2004 Sep 14. Perspect Med Virol. 2003. PMID: 32336841 Free PMC article.
-
Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors.Pathogens. 2017 Dec 12;6(4):65. doi: 10.3390/pathogens6040065. Pathogens. 2017. PMID: 29231855 Free PMC article. Review.
-
Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model.Hum Vaccin Immunother. 2016 Nov;12(11):2959-2968. doi: 10.1080/21645515.2016.1204501. Epub 2016 Jul 19. Hum Vaccin Immunother. 2016. PMID: 27435429 Free PMC article.
References
-
- Aiyar J., Ban M., Bhandari N., Kumar R., Raj P., Sazawal S. Rotavirus-specific antibody response in saliva of infants with rotavirus diarrhea. J. Infect. Dis. 1990;162:1383–1384. - PubMed
-
- Anderson E., Belshe R., Bartram J., Crookshanks-Newman F., Chanock R., Kapikian A. Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children. J. Infect. Dis. 1986;153:823–839. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical